Skip to main content
Key Specialties
Cardiology Diabetology Endocrinology Gastroenterology Geriatrics and Gerontology Gynecology and Obstetrics Hematology Infectious Disease Internal Medicine Nephrology Neurology Oncology Pediatrics Respiratory Medicine Rheumatology Surgery
Congress Coverage
2024 ACC Congress 2023 ESMO Congress 2023 EASD Congress 2023 ERS Congress 2023 ESC Congress
Clinical Collections
Advances in Alzheimer’s

At a glance: The STEP trials

A round-up of the STEP phase 3 clinical trials evaluating semaglutide for weight loss in people with overweight or obesity.
ADVANCED SEARCH
Log in
Top
Familial Cancer

Open Access 25-04-2024 | Pancreatic Cancer | Review

The odyssee from surveillance to the detection of pancreatic cancer, total pancreatectomy, and its impact on life. insights from a p16-Leiden pathogenic variant carrier

Authors: Amarensia (Marit) Spruitenburg, Hans FA Vasen

Published in: Familial Cancer

Login to get access

Excerpt

I will begin my story in March 2001. That’s when pancreatic cancer was diagnosed in my sister. She passed away a month later, leaving us bewildered and sorrowful. She was 49 years old. Shortly after her death, my brother suggested that we contact the Clinical Genetics Center. Our mother had died young, and her sister had also succumbed to pancreatic cancer. My brother had heard from someone that there are families in this region with a hereditary predisposition for melanomas and pancreatic cancer. Both my sister and I had experienced melanomas (Fig 1.) …
Metadata
Title
The odyssee from surveillance to the detection of pancreatic cancer, total pancreatectomy, and its impact on life. insights from a p16-Leiden pathogenic variant carrier
Authors
Amarensia (Marit) Spruitenburg
Hans FA Vasen
Publication date
25-04-2024
Publisher
Springer Netherlands
Published in
Familial Cancer
Print ISSN: 1389-9600
Electronic ISSN: 1573-7292
DOI
https://doi.org/10.1007/s10689-024-00385-0
Webinar | 19-02-2024 | 17:30 (CET)

Keynote webinar | Spotlight on antibody–drug conjugates in cancer

Watch now

Antibody–drug conjugates (ADCs) are novel agents that have shown promise across multiple tumor types. Explore the current landscape of ADCs in breast and lung cancer with our experts, and gain insights into the mechanism of action, key clinical trials data, existing challenges, and future directions.

Dr. Véronique Diéras
Prof. Fabrice Barlesi
Developed by: Springer Medicine
Image Credits